Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series.

Lou E, Sumrall AL, Turner S, Peters KB, Desjardins A, Vredenburgh JJ, McLendon RE, Herndon JE 2nd, McSherry F, Norfleet J, Friedman HS, Reardon DA.

J Neurooncol. 2012 Aug;109(1):63-70. doi: 10.1007/s11060-012-0861-0. Epub 2012 Apr 26.

2.

Atypical and anaplastic meningiomas treated with bevacizumab.

Nayak L, Iwamoto FM, Rudnick JD, Norden AD, Lee EQ, Drappatz J, Omuro A, Kaley TJ.

J Neurooncol. 2012 Aug;109(1):187-93. doi: 10.1007/s11060-012-0886-4. Epub 2012 Apr 29.

PMID:
22544653
3.

Sunitinib for atypical and anaplastic meningioma.

Rahman A.

Lancet Oncol. 2014 Sep;15(10):e424. No abstract available.

PMID:
25328951
4.

Improvement in Visual Fields After Treatment of Intracranial Meningioma With Bevacizumab.

Ly KI, Hamilton SR, Rostomily RC, Rockhill JK, Mrugala MM.

J Neuroophthalmol. 2015 Dec;35(4):382-6. doi: 10.1097/WNO.0000000000000253.

PMID:
26049681
5.

Bevacizumab treatment for meningiomas in NF2: a retrospective analysis of 15 patients.

Nunes FP, Merker VL, Jennings D, Caruso PA, di Tomaso E, Muzikansky A, Barker FG 2nd, Stemmer-Rachamimov A, Plotkin SR.

PLoS One. 2013;8(3):e59941. doi: 10.1371/journal.pone.0059941. Epub 2013 Mar 21.

6.

Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma.

Reardon DA, Norden AD, Desjardins A, Vredenburgh JJ, Herndon JE 2nd, Coan A, Sampson JH, Gururangan S, Peters KB, McLendon RE, Norfleet JA, Lipp ES, Drappatz J, Wen PY, Friedman HS.

J Neurooncol. 2012 Jan;106(2):409-15. doi: 10.1007/s11060-011-0687-1. Epub 2011 Sep 22.

7.

Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancer.

Grisham RN, Iyer G, Sala E, Zhou Q, Iasonos A, DeLair D, Hyman DM, Aghajanian C.

Int J Gynecol Cancer. 2014 Jul;24(6):1010-4. doi: 10.1097/IGC.0000000000000190.

8.

Phase II study of single-agent bevacizumab in Japanese patients with recurrent malignant glioma.

Nagane M, Nishikawa R, Narita Y, Kobayashi H, Takano S, Shinoura N, Aoki T, Sugiyama K, Kuratsu J, Muragaki Y, Sawamura Y, Matsutani M.

Jpn J Clin Oncol. 2012 Oct;42(10):887-95. Epub 2012 Jul 27.

9.

Hydroxyurea with or without imatinib in the treatment of recurrent or progressive meningiomas: a randomized phase II trial by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).

Mazza E, Brandes A, Zanon S, Eoli M, Lombardi G, Faedi M, Franceschi E, Reni M.

Cancer Chemother Pharmacol. 2016 Jan;77(1):115-20. doi: 10.1007/s00280-015-2927-0. Epub 2015 Dec 11.

PMID:
26659583
10.

Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas.

Cuneo KC, Vredenburgh JJ, Sampson JH, Reardon DA, Desjardins A, Peters KB, Friedman HS, Willett CG, Kirkpatrick JP.

Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):2018-24. doi: 10.1016/j.ijrobp.2010.12.074. Epub 2011 Apr 12.

11.

Kinetics of tumor size and peritumoral brain edema before, during, and after systemic therapy in recurrent WHO grade II or III meningioma.

Furtner J, Schöpf V, Seystahl K, Le Rhun E, Rudà R, Roelcke U, Koeppen S, Berghoff AS, Marosi C, Clement P, Faedi M, Watts C, Wick W, Soffietti R, Weller M, Preusser M.

Neuro Oncol. 2016 Mar;18(3):401-7. doi: 10.1093/neuonc/nov183. Epub 2015 Sep 9.

12.

Effect of bevacizumab on intracranial meningiomas in patients with neurofibromatosis type 2 - a retrospective case series.

Alanin MC, Klausen C, Caye-Thomasen P, Thomsen C, Fugleholm K, Poulsgaard L, Lassen U, Mau-Sorensen M, Hofland KF.

Int J Neurosci. 2016 Nov;126(11):1002-6. doi: 10.3109/00207454.2015.1092443. Epub 2015 Oct 6.

PMID:
26365467
13.

Drug review: Safety and efficacy of bevacizumab for glioblastoma and other brain tumors.

Narita Y.

Jpn J Clin Oncol. 2013 Jun;43(6):587-95. doi: 10.1093/jjco/hyt051. Epub 2013 Apr 12. Review.

PMID:
23585688
14.

Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma.

Kaley TJ, Wen P, Schiff D, Ligon K, Haidar S, Karimi S, Lassman AB, Nolan CP, DeAngelis LM, Gavrilovic I, Norden A, Drappatz J, Lee EQ, Purow B, Plotkin SR, Batchelor T, Abrey LE, Omuro A.

Neuro Oncol. 2015 Jan;17(1):116-21. doi: 10.1093/neuonc/nou148. Epub 2014 Aug 6.

15.

Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme.

Lassen U, Sorensen M, Gaziel TB, Hasselbalch B, Poulsen HS.

Anticancer Res. 2013 Apr;33(4):1657-60.

PMID:
23564811
16.

Phase II study of subcutaneous octreotide in adults with recurrent or progressive meningioma and meningeal hemangiopericytoma.

Johnson DR, Kimmel DW, Burch PA, Cascino TL, Giannini C, Wu W, Buckner JC.

Neuro Oncol. 2011 May;13(5):530-5. doi: 10.1093/neuonc/nor044.

17.

Salvage therapy with single agent bevacizumab for recurrent glioblastoma.

Chamberlain MC, Johnston SK.

J Neurooncol. 2010 Jan;96(2):259-69. doi: 10.1007/s11060-009-9957-6. Epub 2009 Jul 11.

PMID:
19593660
18.

Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08).

Wen PY, Yung WK, Lamborn KR, Norden AD, Cloughesy TF, Abrey LE, Fine HA, Chang SM, Robins HI, Fink K, Deangelis LM, Mehta M, Di Tomaso E, Drappatz J, Kesari S, Ligon KL, Aldape K, Jain RK, Stiles CD, Egorin MJ, Prados MD.

Neuro Oncol. 2009 Dec;11(6):853-60. doi: 10.1215/15228517-2009-010.

19.

Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma.

Norden AD, Raizer JJ, Abrey LE, Lamborn KR, Lassman AB, Chang SM, Yung WK, Gilbert MR, Fine HA, Mehta M, Deangelis LM, Cloughesy TF, Robins HI, Aldape K, Dancey J, Prados MD, Lieberman F, Wen PY.

J Neurooncol. 2010 Jan;96(2):211-7. doi: 10.1007/s11060-009-9948-7. Epub 2009 Jun 28.

20.

Regression of a meningioma during paclitaxel and bevacizumab therapy for breast cancer.

Wilson TJ, Heth JA.

J Clin Neurosci. 2012 Mar;19(3):468-9. doi: 10.1016/j.jocn.2011.07.024. Epub 2012 Jan 14.

PMID:
22245272

Supplemental Content

Support Center